A recent experimental study has demonstrated that SSTR3 monoligands activate signaling mechanisms that reduce NF-PitNET cell viability and inhibit pituitary tumor growth in animal models expressing SSTR3, suggesting that it could be an efficacious treatment for NF-PitNETs (42). This evidence concerns the gene SSTR3 and pituitary tumor.